Efficacy and safety of Fufang Biejia Ruangan tablet in patients with chronic hepatitis B complicated with hepatic fibrosis.
- Author:
Ju-mei CHEN
1
;
Yong-ping YANG
;
De-yong CHEN
;
Jin HAN
;
Xue-yuan JIN
;
Ze-xiang HUANG
;
Cheng-bin XU
;
Yan-ming SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Alanine Transaminase; blood; Hepatitis B, Chronic; complications; drug therapy; pathology; Humans; Liver; pathology; physiopathology; Liver Cirrhosis; drug therapy; etiology; pathology; Medicine, Chinese Traditional; Middle Aged; Tablets
- From: Chinese Journal of Experimental and Clinical Virology 2007;21(4):358-360
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical therapeutic effects and safety of Fufang Biejia Ruangan tablet (FBRt) in patients with chronic hepatitis B complicated with hepatic fibrosis.
METHODSTotally 420 patients were randomly divided into two groups, FBRt group (300 cases) were treated with Fufang Biejia Ruangan tablets and control group (120 cases) were treated with He Luo Shu Gan capsule, the patients in both groups were treated for 6 months.
RESULTSThe cure rate and total effective rate of FBRt group were significantly higher than those of control group (55.67 percent and 81.67 percent vs. 15.8 percent and 60.00 percent, P less than 0.01).
CONCLUSIONFufang Biejia Ruangan tablet could alleviate clinical symptoms and hepatic fibrosis. Fufang Biejia Ruangan tablet is effective and safe in treatment of patients with chronic hepatitis B complicated with liver fibrosis.
